We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · July 05, 2021

Delayed Benefit From Aggressive Immunotherapy in Anti-IgLON5 Disease

Neurology(R) neuroimmunology & neuroinflammation

 

Additional Info

Disclosure statements are available on the authors' profiles:

Neurology(R) neuroimmunology & neuroinflammation
Delayed Benefit From Aggressive Immunotherapy in Waxing and Waning Anti-IgLON5 Disease
Neurol Neuroimmunol Neuroinflamm 2021 Jul 01;[EPub Ahead of Print], P Shambrook, A Hesters, C Marois, D Zemba, J Servan, B Gaymard, F Pico, C Delorme, C Lubetzki, I Arnulf, D Psimaras, J Honnorat, A Gales, A Méneret

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading